Cullinan Therapeutics (CGEM) Insider Doyle Buys 21,781 Shares

On June 16, 2026, Mittie Doyle purchased 21,781 shares of Cullinan Therapeutics, Inc. (NasdaqGS: CGEM). The stock was trading at $14.44 at the time of the transaction. This insider buying activity was not part of a pre-planned trading program.

Insider Buying and Selling at Cullinan Therapeutics, Inc.

Several insiders joined Mittie Doyle in acquiring shares of Cullinan Therapeutics on June 16, 2026. Mary Thistle, David Meek, Stephen Webster, and Anthony Rosenberg each bought 25,319 shares, while Andrew Allen purchased 21,781 shares. These transactions were also not pre-planned.

Other Institutional Activity in Cullinan Therapeutics

Among Cullinan's institutional investors, BlackRock, Inc. increased its holdings by 49,670 shares, bringing its total to 4,449,966 shares valued at approximately $63.2 million. State Street Corp also boosted its position with an additional 346,777 shares, ending with 2,544,115 shares worth about $36.2 million. Meanwhile, LYNX1 Capital Management LP, MPM BioImpact LLC, BVF Inc/IL, and Kynam Capital Management, LP maintained their positions without any changes.

Cullinan Therapeutics, Inc. Stock Down 28.7%

Shares of Cullinan Therapeutics traded near $14.44, with a market cap of approximately $887.5 million. The company is not currently profitable, reflected in its lack of a meaningful forward P/E ratio. Over the past year, the stock has seen a low of $5.68 and a high of $16.74. Its 50-day moving average is $14.43, and the 200-day moving average is $11.38. The company's beta is a low 0.007, indicating very little volatility compared to the market.

Analysts Set New Price Targets

On June 11, 2026, Wedbush reiterated its buy rating for Cullinan Therapeutics, setting a price target of $37.00. BTIG also reiterated a buy rating with a target of $38.00. HC Wainwright & Co. maintained its buy rating, setting a target of $30.00. Overall, the consensus among analysts is a strong buy, with a mean target price of $31.55, based on 11 analyst opinions.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. It focuses on developing innovative therapies for autoimmune diseases and cancer. The company is working on several promising candidates, including CLN-978 for autoimmune diseases and CLN-049 for acute myeloid leukemia, both in Phase 1 clinical trials. It also has Zipalertinib, an EGFR inhibitor, in Phase 2b trials for non-small cell lung cancer. Headed by CEO Nadim Ahmed, the company employs 109 people.

Bottom Line

Mittie Doyle's recent share purchase underscores continued insider confidence in Cullinan Therapeutics. Investors often watch insider buying as a potential indicator of a company's future prospects. However, it's important to remember that these transactions are backward-looking and may not reflect current conditions. With strong analyst ratings and ongoing clinical developments, Cullinan Therapeutics remains a company to watch in the biotechnology sector.